Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Thomas M. Bare is active.

Publication


Featured researches published by Thomas M. Bare.


Stroke | 1997

Glycine Site Antagonist Attenuates Infarct Size in Experimental Focal Ischemia Postmortem and Diffusion Mapping Studies

Kentaro Takano; Turgut Tatlisumak; James E. Formato; Richard A. D. Carano; Andreas Bergmann; Linda M. Pullan; Thomas M. Bare; Christopher H. Sotak; Marc Fisher

BACKGROUND AND PURPOSE The glycine site on the N-methyl-D-aspartate (NMDA) receptor complex offers a therapeutic target for acute focal ischemia, potentially devoid of most side effects associated with competitive and noncompetitive NMDA antagonists. METHODS A novel glycine receptor antagonist, ZD9379, was studied in 70 Sprague-Dawley rats using the suture occlusion model of permanent middle cerebral artery occlusion (MCAO). In the first experiment, 20 rats received an initial bolus of vehicle or 10 mg/kg ZD9379 (n = 10 in each group) 30 minutes after MCAO, followed by a continuous infusion of the same dose per hour for 4 hours. Diffusion-weighted MRI with echo-planar acquisition was used to generate maps of the apparent diffusion coefficient (ADC) of water. In a second experiment, 50 rats were assigned to five groups: vehicle and 10, 5, 2.5, and 1 mg/kg ZD9379 (n = 10 in each group) with the same dosing protocol but no imaging. In both experiments, infarct volume was determined by 2,3,5-triphenyltetrazolium chloride staining. RESULTS In the first experiment, before therapy was begun, there was no significant difference in ADC-derived ischemic lesion volume between the two groups. Over time, the 10-mg/kg ZD9379-treated rats had a significant delayed regional recovery of reduced ADC values in the peripheral parietal cortex (P = .0156). Postmortem corrected infarct volume at 24 hours after MCAO was significantly smaller in the group treated with 10 mg/kg ZD9379 than in the vehicle group (119.2 +/- 52.2 versus 211.2 +/- 50.0 mm3 [mean +/- SD]; P = .0008; a reduction of 43.6%). In the second experiment, postmortem corrected infarct volumes in rats receiving 10, 5, and 2.5 mg/kg ZD9379 were significantly smaller than in those receiving vehicle, a reduction of 42.6%, 51.4%, and 42.9%, respectively (P = .0001). CONCLUSIONS This study demonstrates that 2.5- to 10-mg/kg doses of ZD9379 initiated 30 minutes after MCAO significantly reduced infarct size. Diffusion mapping disclosed a delayed treatment effect of this glycine antagonist in focal ischemia, confirmed by the postmortem study.


Bioorganic & Medicinal Chemistry Letters | 1993

Synthesis and activity of spiroisoindolines as novel noncompetitive NMDA antagonists

Thomas M. Bare; Clyde W. Draper; Charles D. McLaren; Linda M. Pullan; Jitendra Patel; Jitendra B. Patel

A series of novel spiroisoindolines was designed and synthesized as potential noncompetitive NMDA antagonists. Affinities of these compounds for the noncompetitive NMDA binding site were determined using [3H]TCP and found to possess IC50s ranging from 0.065 to 17μM. In vivo testing of 2′-methylspiro-[4,5,6,7-tetrahydrobenzothiophene-4,1′-(1,3-dihydroisoindole)] (43) showed it to antagonize NMDA-induced convulsions, to be neuroprotective in a gerbil model of ischemia, and not to generalize to MK-801 in a drug discrimination paradigm.


Journal of Medicinal Chemistry | 1989

Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents

Thomas M. Bare; Charles D. McLaren; James B. Campbell; Judy W. Firor; James F. Resch; Claudia P. Walters; Andre I. Salama; Brad A. Meiners; Jitendra Patel


Journal of Magnetic Resonance Imaging | 1997

Progression of a focal ischemic lesion in rat brain during treatment with a novel glycine/nmda antagonist: An in vivo three-dimensional diffusion-weighted MR microscopy study

Hui Qiu; Laurence W. Hedlund; Sally L. Gewalt; Helene Benveniste; Thomas M. Bare; G. Allan Johnson


Archive | 1983

CNS-Depressant pyrazolopyridines

Thomas M. Bare; Anthony F. Heald


Journal of Medicinal Chemistry | 2007

Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain

Thomas M. Bare; Dean G. Brown; Carey Horchler; Megan Murphy; Rebecca Urbanek; Vernon Alford; Christine Barlaam; Martin C. Dyroff; James B. Empfield; Janet Marie Forst; Keith J. Herzog; Richard Alan Keith; Alan S. Kirschner; Chi-Ming C. Lee; Joseph James Lewis; Frances M. Mclaren; Kathy L. Neilson; Gary Steelman; Shephali Trivedi; Edward P. Vacek; Wenhua Xiao


Archive | 1984

Pyrazolopyridine cycloalkanones and process for their preparation

James B. Campbell; Thomas M. Bare


Archive | 1996

Alpha-substituted pyridazino quinoline compounds

Thomas M. Bare; James Roy Empfield; Janet Marie Forst; Keith J. Herzog; Richard Bruce Sparks


Journal of Heterocyclic Chemistry | 1998

Pyridazino[4,5-b]quinolinediones: Novel glycine/N-methyl-D-aspartate antagonists for the treatment of stroke

Thomas M. Bare


Archive | 1985

Pyrazolo[3,4-b]pyridine-5-carboxamides and their use as anxiolytic agents

Thomas M. Bare

Collaboration


Dive into the Thomas M. Bare's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Megan Murphy

Indiana University Bloomington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge